Arcus Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arcus Biosciences, Inc.
An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.
The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.
Executives said there had been no cases of interstitial lung disease, while ILD – including fatal events – has become a potential problem for AstraZeneca/Daiichi Sankyo’s dato-DXd.
Novartis declined to option BeiGene’s TIGIT inhibitor, ociperlimab. BeiGene will continue a Phase III study combining it with PD-1 inhibitor tislelizumab while dropping another Phase III.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.